Acquisition Opportunity Capillary Biomedical was acquired by Tandem Diabetes Care in July 2022, indicating a potential alignment with Tandem's product ecosystem. For sales outreach, explore integration or co-development conversations around infusion set compatibility and enhanced insulin delivery reliability within Tandem’s existing platforms.

Clinical Collaboration Originating from the Artificial Pancreas Center and continuing academic-industry collaboration suggests a receptive environment for pilots and clinical validation. Propose joint studies or early-access programs for SteadiSet within partner clinics to demonstrate improvements in absorption consistency and patient experience.

Early Stage Scale CapBio operates as a small startup (2-10 employees) with seed-stage funding and a revenue base in the low millions. Target venture-backed diabetes tech initiatives or large healthcare providers seeking innovative infusion sets to differentiate offerings and accelerate adoption.

Product Differentiator SteadiFlow infusion set features kink-proof, soft cannula and user-friendly insertion device, addressing comfort and reliability. Market this as a differentiator to sales teams of existing insulin pump users who experience infusion-site issues or device-related glucose variability.

Strategic Fit The technology stack and focus on insulin delivery intersect with major diabetes technology players and clinics. Position CapBio's infusion set as a complement to established pump ecosystems and as a potential supplier for care networks pursuing improved absorption predictability and streamlined device ecosystems.